Men a conjugate vaccine: could it change epidemiology of meningococcal meningitis in Africa

ABSTRACT

Phase 2 clinical study to assess safety and immunogenicity of meningococcal A [Men A] conjugate vaccine is currently ongoing in Mali and Gambia. The results of the study, which covers children 12- to 23-month-old [the younger age group targeted by mass vaccination campaigns], is expected to be available during the first quarter of 2008. Other studies targeting 2- to 29-year-old [the older age group targeted by the mass vaccination campaigns] are currently going on in four countries Mali, Gambia, Senegal, and India. In addition, a study protocol for use of Men A conjugate vaccine in infants has entered the ethical and regulatory submission process. The study could start as early as June 2008 in Africa